Genetic Technologies announces the development of what it calls the company’s “most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer test.” According to a company press release, this “cutting-edge test represents a significant leap forward in personalized preventative healthcare, providing physicians and their patients with an unprecedented tool to tailor interventions and treatment plans.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
